This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYPositive Net Change LGNDNegative Net Change SRPTPositive Net Change ANIPNegative Net Change
biotechs gene-therapy medical pharmaceuticals
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
GSKPositive Net Change BMYNegative Net Change GILDNegative Net Change EDITNegative Net Change DCPHNo Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
by Zacks Equity Research
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change TSVTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
NVONegative Net Change LGNDNegative Net Change BPMCNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 2, 2024
by Zacks Equity Research
Companies In The News Are: CVS, PFE, PPL, ADP.
PPLNegative Net Change ADPNegative Net Change PFENegative Net Change CVSPositive Net Change
business-services pharmaceuticals utilities
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
by Zacks Equity Research
Pfizer (PFE) beats first-quarter estimates for earnings and sales. It raises 2024 earnings guidance while retaining revenue expectations.
PFENegative Net Change LGNDNegative Net Change ANIPNegative Net Change BNTXNegative Net Change
pharmaceuticals
GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.
GSKPositive Net Change JNJPositive Net Change ANIPNegative Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
LLYPositive Net Change XLVNegative Net Change IYHNegative Net Change IHENegative Net Change PPHNegative Net Change MEDXNegative Net Change
earnings etfs pharmaceuticals
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
ALNYNegative Net Change ATRANegative Net Change ARGXPositive Net Change ANNXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
by Zacks Equity Research
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
EXELPositive Net Change AMRNNegative Net Change ANIPNegative Net Change VYGRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Company News for May 1, 2024
by Zacks Equity Research
Companies In The News Are: PYPL, LLY, MMM, GLW.
LLYPositive Net Change MMMNegative Net Change GLWNegative Net Change PYPLNegative Net Change
communications internet multi-sector-conglomerates pharmaceuticals
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
KONegative Net Change LLYPositive Net Change ETNNegative Net Change
consumer-staples pharmaceuticals utilities
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
NVONegative Net Change LLYPositive Net Change LGNDNegative Net Change ANIPNegative Net Change
pharmaceuticals
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNNegative Net Change PFENegative Net Change NVONegative Net Change AMGNNegative Net Change MRNANegative Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AMZNNegative Net Change KONegative Net Change LLYPositive Net Change MMMNegative Net Change SBUXNegative Net Change MCDNegative Net Change SMCINegative Net Change
consumer-staples multi-sector-conglomerates pharmaceuticals restaurants
Pre-Markets Sell on Last Trading Day of April
by Mark Vickery
Today we close out a month that's likely to be the first negative one since October of last year.
AMZNNegative Net Change KONegative Net Change LLYPositive Net Change MMMNegative Net Change SBUXNegative Net Change MCDNegative Net Change SMCINegative Net Change
consumer-discretionary earnings industrial-products pharmaceuticals
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ALNYNegative Net Change VRTXNegative Net Change CRSPNegative Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNANegative Net Change SRPTPositive Net Change ARGXPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRNegative Net Change EXELPositive Net Change SRPTPositive Net Change COLLNegative Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTPositive Net Change ARGXPositive Net Change OCGNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYPositive Net Change JNJPositive Net Change ABBVNegative Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
SNYNegative Net Change AZNNegative Net Change NVSNegative Net Change JNJPositive Net Change MRKNegative Net Change
pharmaceuticals
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBNegative Net Change LGNDNegative Net Change ANIPNegative Net Change SAGENegative Net Change
biotechs medical pharmaceuticals
PCE/Core PCE Numbers Came In Line With Expectations
by Zacks Equity Research
PCE/Core PCE Numbers Came In Line With Expectations
XOMNegative Net Change ABBVNegative Net Change
oil-energy pharmaceuticals
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
by Mark Vickery
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
XOMNegative Net Change ABBVNegative Net Change
consumer-discretionary consumer-staples energy inflation pharmaceuticals